Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers
NCT02442739
Withdrawn
The primary purpose of this study is to see if it is safe to give patients with pancreatic or head and neck cancer a low dose of the FDA approved anesthetic drug ketamine at the same time they receive radiation and/or chemotherapy for their cancer treatment to prevent depression and its effects. Researchers would also like to see if giving ketamine at the same time as cancer treatment is practical and reasonably acceptable to the patient. New onset depression is highly frequent in those with he... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2018
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Head and Neck Cancer, Pancreatic Cancer, Depression
Register for Updates
Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury
NCT03095222
Withdrawn
The purpose of this study is to identify the optimal dosing strategy for low-dose ketamine infusions in adult acute burn injury patients when used with usual pain medications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2018
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pain
Register for Updates
Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients
NCT03088306
Completed
Patients presenting for lumbar spine surgery experience pain related to their spine condition. Following surgery, these patients also experience surgical pain resulting from disruption of skin, muscle tissue, vertebrae, intervertebral discs, and facet joints. This pain is often treated with opioid medications - with roughly 40% of patient experiencing sub-optimal pain management. Adequate pain control has become a top priority among professional societies, healthcare systems, and accrediting age... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
10/15/2018
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
Register for Updates
Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder
NCT02611921
Completed
The purpose of the study is to determine if intranasal ketamine shows initial evidence of safety, tolerability and efficacy for the treatment of social impairment in individuals with Autism Spectrum Disorder.
Gender:
ALL
Ages:
Between 12 years and 30 years
Trial Updated:
10/10/2018
Locations: Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio
Conditions: Autism Spectrum Disorder
Register for Updates
Ketamine Infusion Therapy for PTSD in Combat Veterans
NCT03088384
Completed
Klarisana is conducting an observational study in San Antonio, Texas to see if there are tangible improvements in the symptoms of post traumatic stress disorder (PTSD) in combat veterans after receiving a series of six low-dose outpatient infusions of ketamine.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/29/2018
Locations: Klarisana, San Antonio, Texas
Conditions: Stress Disorders, Post-Traumatic
Register for Updates
Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer
NCT01653327
Completed
* The primary objective is to determine the reduction in pain score by ketamine mouthwash compared to placebo in head and neck cancer patients with refractory mucositis. * The secondary objectives are to describe the duration of analgesia and adverse effects associated with ketamine and placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2018
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Mucositis, Head and Neck Cancer
Register for Updates
Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain
NCT00899600
Completed
Noxious stimuli occurring intraoperatively and postoperatively generate central sensitization, decreasing pain thresholds and ultimately increasing analgesic requirements. The pathophysiology of central sensitization is thought to involve excitatory amino acid receptors such as N-methyl-d-aspartate (NMDA) (1, 2). Ketamine is a N-methyl-d-aspartate (NMDA) receptor antagonist that has been shown to be useful in the reduction of acute postoperative pain and analgesic consumption in a variety of sur... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/21/2018
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Chronic Low Back Pain
Register for Updates
Rapid Antidepressant Effects of Ketamine in Major Depression
NCT00088699
Completed
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses. Recent preclinical and clinical studies suggest that the glutamatergic system is involved in the mechanism of action of antidepressants. This study examines whether ketamine can cause a rapid-next day antidepressant effect in patients with Major Depressive Disorder. This study was desi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/12/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Depression, Mood Disorders, Major Depresssion
Register for Updates
Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients
NCT02106325
Completed
Investigators will conduct a trial to evaluate the use of Ketamine as an alternate treatment for people with Major Depressive Disorder. This study plans to explore the potential that Ketamine's rapid antidepressant action holds for improving outcomes in patients presenting to the Emergency Department with severe depression. Since this is a controlled trial we will use an IV of Ketamine or and equivalent volume of Diphenhydramine. Subjects will be randomly assigned to receive Ketamine or Benadryl... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/16/2018
Locations: Bellevue Hospital Center, New York, New York +1 locations
Conditions: Depression
Register for Updates
Biomarker Assessment of Glutamatergic Target Engagement
NCT02134951
Completed
The purpose of this study is to assess the relative feasibility of 2 potential functional measures of target engagement (Glx MRS, BOLD fMRI) to systematically assess mGluR 2/3 in drug development for psychotic spectrum disorders.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/15/2018
Locations: University of California Davis, Sacramento, California +2 locations
Conditions: Healthy Controls
Register for Updates
Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine
NCT03290963
Withdrawn
The purpose of this research study is to compare the antidepressant effect of lithium versus placebo in adults receiving ketamine. Lithium is available commercially for depression; ketamine is available commercially and can help the symptoms of depression; however, it has not been approved by the U.S. Food and Drug Administration (FDA) for this use. The FDA has allowed the use of this drug in this research study.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/14/2018
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Treatment Resistant Depression
Register for Updates
Multimodal Analgesia in Cardiac Surgery (Pilot Study)
NCT02734940
Terminated
The investigators objective is to assess the effectiveness of an opioid sparing multimodal approach for enhancing the recovery in Cardiac Surgical patients. This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2018
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Heart Diseases
Register for Updates